New HIV research reveals how broadly neutralizing antibodies may transform treatment despite the virus's rapid mutation and ...

During a live event, Binod Dhakal, MD, discussed the evidence for targeting XPO1 and GPRC5D before BCMA CAR T-cell therapy in multiple myeloma.

Operator: Ladies and gentlemen, thank you for joining, and welcome to the Innate Pharma First Quarter 2026 Business Update and Financial Results.

Inovio Pharmaceuticals remains a high-risk, event-driven play, with the investment case dominated by the binary FDA decision ...

Completed target enrollment in Phase 1 monotherapy dose expansion study of MICVO in 2L+ R/M HNSCC in the first quarter of 2026 Updated data from MICVO Phase 1/2 dose escalation study in combination ...

Introducing a new RNA-seq platform for intracellular multimodal profiling that could transform cancer research and ...

Biologics License Application (BLA) for INO-3107 actively being reviewed under the accelerated approval program by the U.S.

The 2025 Light The Night Executive Challenge raised $10.6 million for Blood Cancer United. Meet three leaders who stepped up.

Reached broad alignment with the FDA on the registration path for CRB-701 for 2L treatment in head and neck squamous cell carcinoma (HNSCC) and cervical cancer with CRB-701Announced presentation of ...

Good afternoon, ladies and gentlemen, and welcome to the Inovio First Quarter 2026 Financial Results Conference Call. [Operator Instructions] This call is being recorded on Wednesday, May 13, 2026. I ...